Literature DB >> 36267162

Attitudes among dermatologists regarding actinic keratosis treatment options.

Gaia Moretta1, Tonia Samela1, Francesca Sampogna1, Francesco Ricci1, Fabio Carlesimo1, Annarita Panebianco1, Angelo Massimiliano D'Erme2, Giovanni Di Lella1, Sabatino Pallotta1, Elena Dellambra1, Damiano Abeni1, Luca Fania1.   

Abstract

Actinic keratosis (AK) is considered a precancerous lesion that can develop into invasive squamous cell carcinoma. Its prevalence is increasing, and it is estimated that it affects between 1% and 44% of the adult population worldwide. Advanced age, fair skin phototypes, and cumulative sun exposure are the main risk factors for AK. Therapies for AK consists of lesion-directed treatment (i.e., cryotherapy, curettage, electrocoagulation, and laser therapy) or field therapy [i.e., photodynamic therapy (PDT), 5-fluorouracil (5-FU), diclofenac sodium (DIC), imiquimod (IMQ), and ingenol mebutate (Ing Meb)]. The type of therapy chosen is determined by the number and location of AKs, the patient's condition, and the patient's tolerability and compliance. In this survey, we collected information from 110 Italian dermatologists about their knowledge and attitudes toward various AK therapeutic approaches. In our study, we discovered that cryotherapy and PDT are the most used treatments for AK, while surgery and laser therapy are the least commonly used. The most commonly used topical therapies are DIC and IMQ 3.75 percent cream, followed by IMQ 5 percent cream, Ing Meb, and 5-FU. The correct treatment for AK can be difficult to choose, but adherence to therapy is critical for good results. Given the high and continuing rise in the incidence of AK, dermatologists' knowledge of various therapeutic approaches is critical. ©Copyright: the Author(s).

Entities:  

Keywords:  actinic keratosis; dermatology; non-melanoma; skin tumor; therapy

Year:  2022        PMID: 36267162      PMCID: PMC9577376          DOI: 10.4081/dr.2022.9392

Source DB:  PubMed          Journal:  Dermatol Reports        ISSN: 2036-7392


  23 in total

Review 1.  The importance of treating the field in actinic keratosis.

Authors:  E Stockfleth
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-03       Impact factor: 6.166

2.  S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators.

Authors:  Markus V Heppt; Ulrike Leiter; Theresa Steeb; Teresa Amaral; Andrea Bauer; Jürgen C Becker; Eckhard Breitbart; Helmut Breuninger; Thomas Diepgen; Thomas Dirschka; Thomas Eigentler; Michael Flaig; Markus Follmann; Klaus Fritz; Rüdiger Greinert; Ralf Gutzmer; Uwe Hillen; Stephan Ihrler; Swen Malte John; Oliver Kölbl; Klaus Kraywinkel; Christoph Löser; Dorothée Nashan; Seema Noor; Monika Nothacker; Christina Pfannenberg; Carmen Salavastru; Lutz Schmitz; Eggert Stockfleth; Rolf-Markus Szeimies; Claas Ulrich; Julia Welzel; Kai Wermker; Carola Berking; Claus Garbe
Journal:  J Dtsch Dermatol Ges       Date:  2020-03       Impact factor: 5.584

3.  Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis.

Authors:  Magdalene A Dohil
Journal:  J Drugs Dermatol       Date:  2016-10-01       Impact factor: 2.114

Review 4.  Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology.

Authors:  Thomas Dirschka; Girish Gupta; Giuseppe Micali; Eggert Stockfleth; Nicole Basset-Séguin; Véronique Del Marmol; Reinhard Dummer; Gregor B E Jemec; Josep Malvehy; Ketty Peris; Susana Puig; Alexander J Stratigos; Iris Zalaudek; Giovanni Pellacani
Journal:  J Dermatolog Treat       Date:  2016-11-13       Impact factor: 3.359

5.  Actinic keratosis: correlation between clinical and histological classification systems.

Authors:  L Schmitz; P Kahl; M Majores; E Bierhoff; E Stockfleth; T Dirschka
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-03-08       Impact factor: 6.166

6.  Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain.

Authors:  I Elías; N Ortega-Joaquín; P de la Cueva; L J Del Pozo; D Moreno-Ramírez; A Boada; M Aguilar; A Mirada; E Mosquera; C Gibbons; I Oyagüez
Journal:  Actas Dermosifiliogr       Date:  2016-04-26

Review 7.  How to treat actinic keratosis? An update.

Authors:  Claudia Costa; Massimiliano Scalvenzi; Fabio Ayala; Gabriella Fabbrocini; Giuseppe Monfrecola
Journal:  J Dermatol Case Rep       Date:  2015-06-30

8.  Guidelines of care for the management of actinic keratosis.

Authors:  Daniel B Eisen; Maryam M Asgari; Daniel D Bennett; Suzanne M Connolly; Robert P Dellavalle; Esther E Freeman; Gary Goldenberg; David J Leffell; Sue Peschin; James E Sligh; Peggy A Wu; Lindsy Frazer-Green; Sameer Malik; Todd E Schlesinger
Journal:  J Am Acad Dermatol       Date:  2021-04-02       Impact factor: 11.527

Review 9.  Daylight Photodynamic Therapy: An Update.

Authors:  Chaw-Ning Lee; Rosie Hsu; Hsuan Chen; Tak-Wah Wong
Journal:  Molecules       Date:  2020-11-08       Impact factor: 4.411

10.  Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome.

Authors:  Khaled Ezzedine; Caroline Painchault; Melanie Brignone
Journal:  J Mark Access Health Policy       Date:  2020-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.